Ruxolitinib-Induced Complete Molecular Remission in Polycythemia Vera (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-637; Location: LEVEL 3, HALL B3; "Ruxolitinib (RUX) is a JAK inhibitor approved for treating patients with PV who are nonresponsive to or intolerant of hydroxyurea (HU) and who have demonstrated improved hematocrit control, symptom burden, and reduced variant allele fraction (VAF) vs best available therapy. This patient's hematologic, molecular, and histopathological response to RUX suggests the potential of JAK2 inhibitor-targeted clearance of MPN HSPCs, yet it remains unproven that malignant HSPC eradication is reliably achieved with JAK inhibitors and if this is necessary to achieve cure. A retrospective analysis of patients with PV treated with RUX who achieved deep molecular response might identify determinants of RUX molecular response and potential for cure. BCR::ABL1: breakpoint cluster region–Abelson oncogene homolog 1 fusion gene, CMR: complete molecular remission, EFS: event-free survival, HSPCs: hematopoietic stem and progenitor cells, JAK2: Janus kinase 2, JAK-STAT: Janus..."
Clinical • Essential Thrombocythemia • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • ABL1 • BCR
|
|
Nooshin Beygui MD 1; John Mascarenhas MD 2
|